The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Advanced image-free robotic platform to support greater precision, personalised planning, and improved patient outcomes
The clearance marks a pivotal step forward for the company as it pushes deeper into AI-driven diagnostics and expands its clinical footprint in point-of-care imaging
IIT Kanpur team has developed computational framework to map how cell signals influence gene activity across tissues
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Investment will support LifeSigns’ global expansion across Southeast Asia and GCC markets
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Mumbai event on June 24–25 will spotlight real-world impact of pharmacovigilance beyond AI adoption
Subscribe To Our Newsletter & Stay Updated
